Fifth-Generation Cephalosporins

This cephalosporin is particularly notable for its activity against Methicillin-Resistant Staphylococcus Aureus (MRSA), making it a key option in treating infections caused by this resistant organism.

Ceftaroline (IV):
- It is one of the fifth-generation cephalosporins, positioned distinctively due to its advanced capability to bind to penicillin-binding protein 2a, a protein integral to bacterial cell wall synthesis.
- Ceftaroline fosamil:
  - This drug is a prodrug converted into the active metabolite, ceftaroline, which is utilized for therapeutic purposes.
- Mechanism of Action:
  - Ceftaroline’s increased binding affinity to penicillin-binding protein 2a provides bactericidal activity against MRSA.
  - This gives it a critical role in the treatment of serious skin infections resulting from resistant bacteria.
- Spectrum of Activity:
  - While ceftaroline has broad activity against Gram-negative bacteria, it is important to note that it is not active against Pseudomonas aeruginosa due to its ineffectiveness against AmpC and extended-spectrum beta-lactamase-producing organisms.
- Dosing and Administration:
  - Commonly administered as 600 mg infused every 12 hours for skin and soft tissue infections or community-acquired pneumonia.
  - In more severe cases such as bacteremia, endocarditis, and osteomyelitis, it can be given at 600 mg every 8 hours, sometimes in combination with other agents.
- Pharmacokinetics:
  - The half-life of ceftaroline is approximately 2.7 hours, indicating the need for regular dosing to maintain therapeutic levels in the bloodstream.
- Excretion:
  - Ceftaroline is primarily excreted through the renal system, necessitating renal adjustments to dosing in patients with impaired kidney function to avoid accumulation and potential toxicity.